Nice and Saclay, November 2025 AlgenScribe has announced the successful completion of an equity financing round, raising €470,000. This investment will support the ongoing development of its innovative platform, which integrates synergistic molecular biology tools designed to tackle multiple challenges in the field of gene editing. The company has entered into its first collaboration with an American foundation, marking a significant milestone. The new scientific program

Nice, le 07 janvier 2025. Fondée fin 2022, AlgenScribe se positionne sur le marché très dynamique de la médecine génomique avec la...

25 of July 2024 The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from France have agreed to cooperate to further...

5 September 2023 ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement License allows AlgenScribe to expand its research...